TrialNature medicine2024

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.

Claire F Friedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.